These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 26302596)
1. WHAT'S ON THE HORIZON. A LOOK AT NEW DRUGS IN DEVELOPMENT. Horn T Posit Aware; 2015; 27(2):68-9. PubMed ID: 26302596 [No Abstract] [Full Text] [Related]
2. What's in the works. Horn T Posit Living; 2001 Feb; 10(2):20-2. PubMed ID: 11548496 [No Abstract] [Full Text] [Related]
3. What's new and what's next. Fakuda D Posit Dir News; 1998 Jan; 10(1):25-9. PubMed ID: 11365053 [TBL] [Abstract][Full Text] [Related]
5. Study of anti-HIV gel shows promise--what's the next step? Look to upcoming results from Phase III trial. AIDS Alert; 2009 May; 24(5):55-7. PubMed ID: 19452649 [No Abstract] [Full Text] [Related]
6. The design of drugs for HIV and HCV. De Clercq E Nat Rev Drug Discov; 2007 Dec; 6(12):1001-18. PubMed ID: 18049474 [TBL] [Abstract][Full Text] [Related]
7. Designer drugs. What's best for patients isn't always what's best for profits. Sherrid P US News World Rep; 2001 Aug; 131(6):30-2. PubMed ID: 11508075 [No Abstract] [Full Text] [Related]
8. New AZT analogues having 5'-alkylsulfonyl groups: synthesis and anti-HIV activity. Al-Masoudi NA; Al-Soud YA; Ali IA; Schuppler T; Pannecouque C; De Clercq E Nucleosides Nucleotides Nucleic Acids; 2007; 26(3):223-30. PubMed ID: 17454731 [TBL] [Abstract][Full Text] [Related]
9. HIV treatment update: what's new in 2002? Averitt D WORLD; 2002 Apr; (132):5. PubMed ID: 12038463 [No Abstract] [Full Text] [Related]
10. Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery. Timmins P; Brown J; Meanwell NA; Hanna GJ; Zhu L; Kadow JF Drug Discov Today; 2014 Sep; 19(9):1288-93. PubMed ID: 24727410 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and anti-HIV-1 activities of novel podophyllotoxin derivatives. Chen SW; Wang YH; Jin Y; Tian X; Zheng YT; Luo DQ; Tu YQ Bioorg Med Chem Lett; 2007 Apr; 17(7):2091-5. PubMed ID: 17317161 [TBL] [Abstract][Full Text] [Related]
12. Anti-HIV drug updates--three drugs on the near horizon. Proj Inf Perspect; 2003 Jan; (35):4-7. PubMed ID: 12647672 [TBL] [Abstract][Full Text] [Related]
13. What's new, what's next? Elwell A Posit Dir News; 1999; 11(1):1, 3-13. PubMed ID: 11366098 [TBL] [Abstract][Full Text] [Related]
15. [d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor. Hunter R; Muhanji CI; Hale I; Bailey CM; Basavapathruni A; Anderson KS Bioorg Med Chem Lett; 2007 May; 17(9):2614-7. PubMed ID: 17317163 [TBL] [Abstract][Full Text] [Related]
16. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Johns BA; Weatherhead JG; Allen SH; Thompson JB; Garvey EP; Foster SA; Jeffrey JL; Miller WH Bioorg Med Chem Lett; 2009 Mar; 19(6):1802-6. PubMed ID: 19217781 [TBL] [Abstract][Full Text] [Related]
17. After the drugs: what's next? Schouten JT Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085 [TBL] [Abstract][Full Text] [Related]
18. New anti-HIV drugs in development. Proj Inf Perspect; 1999 Sep; (28):4-8. PubMed ID: 11367365 [TBL] [Abstract][Full Text] [Related]
19. Pipeline update: short notes on new anti-HIV drugs in development. Proj Inf Perspect; 2006 Oct; (42):11-6. PubMed ID: 17162806 [No Abstract] [Full Text] [Related]
20. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come. Tan SY Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964 [No Abstract] [Full Text] [Related] [Next] [New Search]